Chromax® supports weight loss

PURCHASE, N.Y.

Nutrition 21 Inc., the developer and marketer of nutritional supplements under the Iceland Health® and Diabetes Essentials brands, reported a randomized, double blind, placebo-controlled clinical study published online in Diabetes Technology & Therapeutics showed Chromax® chromium picolinate significantly reduced hunger levels by 24%, food intake by 25% and reduced cravings for high-fat foods in adult non-diabetic overweight women. The study was conducted by researchers at the Pennington Biomedical Research Center.
“Study subjects were allowed to eat any type and amount of food throughout the study. The participants who received chromium picolinate reduced their caloric intake by an average of 365 calories per day between their baseline and final (week 8) visit,” stated Steve Anton, Ph.D., investigator and lead author of the publication. “Not only are these results clinically significant, it is also noteworthy that participants receiving chromium picolinate did not report increased hunger levels despite significantly reducing their food intake.”

James Komorowski, M.S., vice president of technical services and scientific affairs for Nutrition 21, stated, “These results show that Chromax chromium picolinate can be useful for overweight individuals desiring to reduce their food intake. The published study also provides clinical substantiation for reduced hunger and reduced cravings claims for food and supplement manufacturing companies that use Chromax in their formulations.”

The randomized, double blind, placebo-controlled, eight-week study population comprised 42 overweight adult women who reported craving carbohydrates. Subjects were administered either Chromax chromium picolinate capsules (containing 1,000 mcg chromium) or matching placebo capsules for eight weeks. Food intake was directly measured at the research center’s eating laboratory at baseline, after one week and again after eight weeks.

Michael A. Zeher, president and CEO of Nutrition 21, commented, “The results of this study provide substantial evidence of the efficacy of Chromax in decreasing hunger and high-fat cravings. We are pleased that a renowned research center the caliber of the Pennington Biomedical Research Center, has completed independent research that validates the potential benefits of using Chromax on food intake and satiety levels. This new use can easily be incorporated within the framework of a sensible weight loss program. With a patent covering the use of chromium for reducing food cravings and appetite, Nutrition 21 is, again, in the right place, at the right time with safe and effective science-based products for our customers and consumers seeking solutions to their health care needs.”